Proteolytic cleavage of the Amyloid protein precursor (APP) gives rise to the beta-Amyloid and Amyloid A4 proteins, which are present in human platelets.
Amyloid deposition is associated with type II diabetes, Down syndrome and a variety of neurological disorders, including Alzheimer’s disease.
Proteolytic cleavage of APP leads to the formation of the Amyloid beta/A4 Amyloid protein.
This protein is involved in the formation of neurofibrillary tangles and plaques that characterize the senile plaques of Alzheimer’s patients.
BBP (Beta-amyloid-binding protein), also known as TM2D1 (TM2 domain-containing protein 1), is a 207 amino acid multi-pass membrane protein containing a G protein-coupling module that allows for interaction with the beta-amyloid peptide of APP.
In cell culture, expression of BBP induces caspase-dependent vulnerability to beta-amyloid peptide toxicity, suggesting that it is a target of beta-amyloid and may be involved in the molecular pathophysiology of Alzheimer’s disease.
Applications:Suitable for use in Western Blot.
Other applications not tested.
Recommended Dilution:Western Blot: 1:500-1:1000Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20°C.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ul
Host：rabbit
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by immunoaffinity chromatography.
Form：Supplied as a liquid PBS, 0.1% sodium azide, 50% glycerol.
Specificity：Recognizes endogenous levels of BBP. Species Crossreactivity: Human, mouse
Isotype：IgG
Calc Applications Abbrev：WB
Calc Crossreactivity：Hu Mo
Immunogen：A synthetic peptide corresponding to residues in Human BBP.
